Form 4 Filing for KalVista Pharmaceuticals, Inc. - Insider Transactions

This filing details insider transactions for Nicole Sweeny, Chief Commercial Officer at KalVista Pharmaceuticals, Inc. On April 16, 2026, Ms. Sweeny acquired 6,250 shares of Common Stock through the settlement of Restricted Stock Units (RSUs) with no cost, as per footnote F1. These RSUs vest quarterly, with 1/16th vesting each quarter starting April 16, 2026, subject to continued service. Following this, she held 53,253 shares. On April 17, 2026, Ms. Sweeny sold 1,862 shares of Common Stock at $20.2163 per share. This sale was to cover tax withholding obligations related to the vesting and settlement of RSUs, as indicated by footnote F2, and was executed as a "sell to cover" transaction, not a discretionary trade. After this transaction, her holdings decreased to 51,391 shares. The filing also notes a derivative transaction involving 6,250 RSUs, with each RSU representing a contingent right to one share of Common Stock.